|
Oxford Biomedica is to shed about nine of the 90 jobs at its gene therapy business in Oxford. 01-Sep-2008 Oxford Biomedica has acquired Oxxon Therapeutics, the Oxford-based therapeutic vaccines company, for £16m. 13-Mar-2007 Oxford Biomedica is to raise £30m in a share placing to fund the commercial development of its gene therapy research business. 17-Nov-2005 Oxford Biomedica, the gene therapy company with a market capitalisation of £85m, has received a takeover approach from an unnamed company. 20-Jan-2005 Oxford Biomedica has won a £0.5m grant to research treatments for Haemophilia A, as part of a £4m investment in gene therapy by the Department of Health. 31-Mar-2004 Oxford Biomedica is planning to raise £20m in a rights issue, in order to strengthen its balance sheet and prepare for the negotiation of new drug licensing deals. 17-Sep-2003 Oxford Biomedica is planning to raise up to £30m in a share offer in order to fund international expansion and clinical trials for new gene therapy-based products. 05-Mar-2001 Oxford Biomedica is seeking a partner to fund the development of its TroVax cancer vaccine, and is also planning to seek a listing on London's main market. 03-Jan-2001 Oxford Biomedica has raised £8.5m in a share placing in order to set up a new gene division, and the proceeds will be spent on the recruitment of scientists and the marketing of two new technologies. 10-Aug-2000 Oxford Biomedica has raised a further £5m in a share issue for the development of gene therapy, and is looking to move from the Alternative Investment Market to a full stockmarket listing. 19-Jan-2000 Oxford Biomedica is forming a joint venture with ViroMed of South Korea to develop gene therapies against cancer. 20-May-1999 Oxford Biomedica is planning to raise £3.6m in a rights issue to fund clinical trials for its gene therapy projects. 04-Mar-1999 Oxford Biomedica is forming an alliance with Rhone Poulenc's RPR Gencell division in the US to develop gene therapy technology for heart disease. 14-Dec-1998 Oxford Biomedica is planning to raise £6m in a rights issue, and plans to begin clinical trials on two cancer drugs this year. 27-Feb-1998 Oxford Biomedica is to undertake joint research into gene therapy with Rhone-Poulenc Rorer of the US, and hopes to reach similar agreements with other US companies. 27-Jan-1998 Oxford Biomedica is seeking additional funds of up to £10m to fund research into cancer treatments, following its failure to raise sufficient funds when it launched on the Alternative Investment Market in December. 04-Aug-1997 Oxford Biomedica, the gene-therapy concern, is planning a public share offer in November in order to raise £5m for the funding of a lease on a site in Oxford and the recruitment of up to 30 staff. 09-Sep-1996
|